Disease severity in children and adults with Pompe disease related to age and disease duration

Neurology

Volumn 64, Issue 12, 2005, Pages 2139-2141

  Hagemans, M L C ^a,b   Winkel, L P F ^a   Hop, W C J ^b   Reuser, A J J ^b   Van Doorn, P A ^b   Van Der Ploeg, A T ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; ASSISTED VENTILATION; CHILD; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ENZYME THERAPY; FEMALE; FOLLOW UP; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; QUESTIONNAIRE; WHEELCHAIR;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MUSCLE, SKELETAL; QUESTIONNAIRES; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; WHEELCHAIRS;

EID: 21144449402     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000165979.46537.56     Document Type: Article

References (10)

1. Hirschhorn R, Reuser AJJ. Glycogen storage disease type II; acid α-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly W, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001:3389-3420.
2. Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in the Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 1999;7:713-716.
3. Martiniuk F, Chen A, Arvanitopoulos E, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 1998;79: 69-72.
4. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356:397-398.
5. Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004;113:e448-e457.
6. Winkel LP, Van den Hout JM, Kamphoven JH, et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 2004;55:495-502.
7. Hinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromusc Disord 2005;15:24-31.
8. Hagemans ML, Janssens AC, Winkel LP, et al. Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 2004;63:1688-1692.
9. Hagemans ML, Winkel LP, Van Doorn PA, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005;128:671-677.
10. Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr 2000;137:283-285.